We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis (ITRACONASP)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01259336
First Posted: December 14, 2010
Last Update Posted: February 22, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Vishwanath gella, Postgraduate Institute of Medical Education and Research
  Purpose
The purpose of this study is to determine whether there itraconazole is effective in the treatment of chronic cavitary pulmonary aspergillosis

Condition Intervention Phase
Chronic Cavitary Pulmonary Aspergillosis Drug: Itraconazole Drug: treatment in cavitary pulmonary aspergillosis Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS

Resource links provided by NLM:


Further study details as provided by Vishwanath gella, Postgraduate Institute of Medical Education and Research:

Primary Outcome Measures:
  • clinical improvement in cough and hemoptysis [ Time Frame: 6 months ]
    Clinical response- assessed by a decrease in frequency & intensity of hemoptysis & cough. Significant clinical response will be considered if there is no recurrence of episodes of moderate-massive hemoptysis. Number of interventions required to control hemoptysis will also be taken as a measure of clinical response


Secondary Outcome Measures:
  • Radiological response of CCPA to itraconazole [ Time Frame: 6 months ]
    1. Complete response- It is defined as complete disappearance of the aspergilloma.
    2. Partial response- It is defined as 30% decrease in the sum of the longest diameters of all the lesions.
    3. Progressive disease- It is defined as appearance of any new lesions or >20% increase in the sum of the longest diameters of all measurable lesions.
    4. Stable disease- Shrinkage or growth of CCPA that does not meet any of these criteria


Enrollment: 31
Study Start Date: July 2010
Study Completion Date: December 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Itraconazole
Role of itraconazole in CCPA
Drug: Itraconazole
Tablet 200 mg twice daily for 6 months
Other Name: Study group
Drug: treatment in cavitary pulmonary aspergillosis
Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
Experimental: treatment in cavitary pulmonary aspergillosis
Patients in this arm are given conservative management with antitussives, brochial artery embolisation.
Drug: treatment in cavitary pulmonary aspergillosis
Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)

Detailed Description:
The role of itraconazole is still not clear in the treatment of chronic cavitary pulmonary aspergillosis(CCPA). Some studies have shown a beneficial role of itraconazole in reducing hemoptysis. So the present study is aimed at analyzing the role of itraconazole in CCPA.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Inclusion Criteria:

    1. Clinical symptoms: -presence of chronic pulmonary/systemic symptoms lasting ≥ six weeks.
    2. Radiological findings:

      • Evidence of slowly progressive pulmonary lesions over weeks-months including cavities with surrounding inflammation.
      • presence of intracavitary mass with a surrounding crescent of air,and presence of pleural thickening in peripheral lesions.
    3. Microbiological/Immunological findings: Positive results in the aspergillus precipitin test, demonstration of aspergillus hyphae in sputum or BAL fluid or cultures of BAL/sputum growing aspergillus species.
  2. The diagnosis of CCPA will be made if

    1. Patient satisfies at least 1, 2a or 2b and/ or any of the 3rd criteria.
    2. FNAC from the cavity wall will be considered in atypical cases
  3. Exclusion Criteria:

    1. Invasive aspergillosis
    2. Allergic broncho-pulmonary aspergillosis (ABPA)
    3. Active tuberculosis or malignancy
    4. Pregnant females
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01259336


Locations
India
PGIMER
Chandigarh, Punjab, India, 160012
Sponsors and Collaborators
Postgraduate Institute of Medical Education and Research
Investigators
Principal Investigator: Vishwananath gella, DM POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Vishwanath gella, vgella, Postgraduate Institute of Medical Education and Research
ClinicalTrials.gov Identifier: NCT01259336     History of Changes
Other Study ID Numbers: Itracon asp
First Submitted: December 6, 2010
First Posted: December 14, 2010
Last Update Posted: February 22, 2012
Last Verified: November 2010

Keywords provided by Vishwanath gella, Postgraduate Institute of Medical Education and Research:
Itraconazole
chronic cavitary pulmonary aspergillosis
Aspergillosis
fungal ball
mycetoma
efficacy
safety

Additional relevant MeSH terms:
Aspergillosis
Pulmonary Aspergillosis
Mycoses
Hyalohyphomycosis
Dermatomycoses
Lung Diseases, Fungal
Skin Diseases, Infectious
Skin Diseases
Lung Diseases
Respiratory Tract Diseases
Itraconazole
Hydroxyitraconazole
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors